Amgen's Dazodalibep Study Advances Sjögren's Syndrome Treatment Options

Amgen Inc has announced an update on its ongoing clinical study for dazodalibep, a drug for treating Sjögren's Syndrome. The long-term extension study aims to evaluate the safety and tolerability of the drug over an extended period. The study is currently ongoing with recruitment and progress updates. This development could positively influence Amgen's stock performance and position the company competitively in the pharmaceutical industry.

Amgen Inc. (AMGN) has recently announced an update on its ongoing Phase 2 clinical study for dazodalibep, a drug designed to treat Sjögren's Syndrome. The study, titled "A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren’s Syndrome," aims to assess the drug's effectiveness and safety over an extended period [1].

The long-term extension study started on May 9, 2024, and is expected to complete by mid-2025. The primary goal is to evaluate the drug's safety and tolerability over an extended period, which is crucial for understanding its long-term benefits and potential side effects. The study employs a randomized, parallel assignment model with quadruple masking, ensuring unbiased results [1].

The study is currently recruiting participants, and progress updates are available on the ClinicalTrials portal. This development could positively influence Amgen's stock performance, as successful results may lead to a new marketable treatment, boosting investor confidence. The study's progress is crucial in a competitive industry where advancements in autoimmune disease treatments are highly valued [1].

In addition to this clinical update, Amgen has seen increased institutional investment in its shares. CW Advisors LLC recently increased its stake in Amgen by 5.5%, acquiring a total of 76,963 shares valued at approximately $23.99 million [2]. This increase follows a strong quarterly earnings report, with Amgen reporting $6.02 EPS, exceeding analysts' expectations of $5.28, alongside a revenue of $9.18 billion, up 9.4% year-over-year [2].

Amgen also announced a quarterly dividend of $2.38 per share, yielding 3.2%, with a dividend payout ratio of 77.84%. The company has set its FY 2025 guidance at 20.200-21.300 EPS, and analysts anticipate that Amgen Inc. will post 20.62 EPS for the current fiscal year [2].

The company's stock has shown resilience, with a one-year low of $253.30 and a one-year high of $339.17. The stock has a market capitalization of $159.60 billion, a PE ratio of 24.24, and a beta of 0.49. Amgen's debt-to-equity ratio is 7.24, and the quick ratio is 0.98 [2].

References:
[1] https://www.theglobeandmail.com/investing/markets/stocks/AMGN/pressreleases/34352638/amgens-phase-2-study-on-hzn-1116-a-potential-breakthrough-for-sjogrens-syndrome/
[2] https://www.marketbeat.com/instant-alerts/filing-amgen-inc-amgn-shares-bought-by-cw-advisors-llc-2025-08-21/